The company is located in the Jiangbei New Area of Nanjing National-level Free Trade
Zone, covering an area of 20 hectares with a total investment of approximately 1.87
billion yuan, and has been included in the "Major Economic and Social Development.Projects of Nanjing City from 2020 to 2023". The main business includes R&D, production, and sales of APIs, traditional Chinese medicine extracts and preparations, and biologics, with core therapeutic areas covering cardiovascular, tumor.